Altace
(Ramipril)ApprovedSmall molecule
Ramipril is used to treat high blood pressure and heart failure by helping blood vessels relax and allowing blood to flow more easily. It can also help reduce the risk of heart attack and stroke in people with heart disease.[2] Altace is currently approved and in use across 34 indications[4].[1]
Altace is one of 646 small molecule programs targeting Essential Hypertension. It is currently in Approved.
34
Indications
115
Total Trials
9
Active Trials
645
Competitors
3
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 34 indications
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Altace
VViking Therapeutics, Inc.
Approved
Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension10 trials
Show 7 more trials
Fasting Conditions8 trials
Show 5 more trials
Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions
Completed·—·Phase 1·NCT01164761·54 enrolled
Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions
Completed·—·Phase 1·NCT01164774·54 enrolled
Essential Hypertension7 trials
Show 4 more trials
Intensive Vasodilator Therapy in Patients With Essential Hypertension
Completed·—·Phase 4·NCT01180413·48 enrolled
Endothelial Dysfunction4 trials
Show 1 more trial
Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Unknown status·—·Phase 4·NCT01743014·60 enrolled
62 more indications
Safety and Efficacy3 trials
Albuminuria3 trials
Female3 trials
Fed3 trials
Hypertensive3 trials
Fibrosis2 trials
Diabetes2 trials
Type 2 Diabetes2 trials
Proteinuria2 trials
Acute Myocardial Infarction2 trials
Nephropathy2 trials
Atherosclerosis2 trials
The Study of Atherosclerosis With Ramipril and Rosiglitazone
Completed·—·Phase 3·NCT00140647·1,200 enrolled
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
Completed·—·Phase 2·NCT00054938·150 enrolled
Alport syndrome2 trials
Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
Not yet recruiting·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT05133050·510 enrolled
Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
Completed·IInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbH·Phase 3·NCT01485978·66 enrolled
Effectiveness1 trial
Fibrinolysis1 trial
Type 1 Diabetes1 trial
Cardiac Allograft Vasculopathy1 trial
Cardiovascular Events1 trial
Acute Coronary Syndrome1 trial
Telmisartan Versus Ramipril After Acute Coronary Syndrome
Unknown status·—·Phase 4·NCT00702936·50 enrolled
Cardiomyopathy1 trial
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
Not yet recruiting·—·Phase 1·NCT06304896·150 enrolled
Systemic Lupus Erythematosus1 trial
Efficacy1 trial
Allograft1 trial
Systolic Heart Failure1 trial
Blood Pressure1 trial
Combination Therapy1 trial
ESS1 trial
Cardiovascular1 trial
Single Dose1 trial
Insulin resistance1 trial
Microvascular Dysfunction1 trial
Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction
Completed·—·Phase 4·NCT02525081·63 enrolled
Carvedilol1 trial
Ramipril Versus Carvedilol in Duchenne and Becker Patients
Unknown status·—·Phase 4·NCT00819845·194 enrolled
Atrial Fibrillation1 trial
Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Terminated·—·Phase 3·NCT00736294·198 enrolled
Metabolic Syndrome1 trial
Cardiotoxicity1 trial
Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab
Unknown status·—·Phase 3·NCT02236806·262 enrolled
Post-Operative Atrial Fibrillation1 trial
Peripheral Arterial Disease1 trial
The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease
Completed·—·Phase 4·NCT00168467·40 enrolled
Kidney Disease1 trial
African American Study of Kidney Disease and Hypertension
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT04364139·1,094 enrolled
Gene Expression1 trial
Pediatric Patients1 trial
Ramipril in Pediatric Patients on Hemodialysis
Completed·—·Phase 2/3·NCT04582097·135 enrolled
Medication1 trial
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Completed·—·Phase 3·NCT00095654·5,000 enrolled
Inflammation1 trial
Chronic Kidney Disease1 trial
Catheter1 trial
Renal Transplant1 trial
Regulatory
FDA Approval Timeline[5]
Jan 28, 1991
ALTACE
NDA NDA019901
Feb 27, 2007
ALTACE
NDA NDA022021
Jul 23, 2025
VOSTALLY
NDA NDA219757
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Altace drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ramipril. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Altace. U.S. Food & Drug Administration.
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Angiotensin-Converting Enzyme Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- VViking Therapeutics, Inc.
Patent Landscape[6]
Patent Cliff
Aug 16, 2039
Earliest patent expiration — generic entry possible after this date
Patent #Expires
12343338Aug 16, 2039